Evaluation of the LightSheer HS Hand Piece as Compared to the LightSheer ET Hand Piece for the Intended Use of Hair Removal and Permanent Hair Reduction

Sponsor
Lumenis Ltd. (Industry)
Overall Status
Completed
CT.gov ID
NCT00657085
Collaborator
(none)
5
1
9
0.6

Study Details

Study Description

Brief Summary

To observe the qualitative comparison of follicular damage between treatment with the LightSheer Duet hand pieces (ET and HS) as assessed by horizontal biopsy.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    5 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Evaluation of the LightSheer HS Hand Piece as Compared to the LightSheer ET Hand Piece for the Intended Use of Hair Removal and Permanent Hair Reduction
    Study Start Date :
    Mar 1, 2008
    Actual Primary Completion Date :
    Dec 1, 2008
    Actual Study Completion Date :
    Dec 1, 2008

    Outcome Measures

    Primary Outcome Measures

    1. Follicular damage assessed by histology [first visit]

    Secondary Outcome Measures

    1. Comparison of permanent hair reduction between ET and HS handpieces [2 month follow up visit]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. Healthy male adult, 18 years of age or older with skin type I-V;

    2. Having a suitable treatment area for hair removal with brown or black hair (no gray);

    3. Able and willing to comply with the treatment/follow-up schedule and requirements;

    4. Able to read, understand and provide written Informed Consent.

    Exclusion Criteria:
    1. Showing symptoms of hormonal disorders, as per the Investigator's discretion;

    2. Use of oral isotretinoin (Accutane®) within 6 months, or off label use of topical isotretinoin in immediate treated area or in its proximity within 3 months, of study enrollment or during the course of the study;

    3. Prior skin treatment with laser or other devices on the same treated areas prior to study enrollment or during the course of the study;

    4. Adverse reaction to the treatment gel to be used in the evaluation;

    5. History of keloid formation or poor wound healing in a previously injured skin area;

    6. Significant skin conditions affecting treated area or inflammatory skin conditions;

    7. Open laceration, abrasion, active cold sores or herpes sores on area to be treated;

    8. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications;

    9. Having a bleeding disorder or taking anticoagulation medications within the preceding 6 months;

    10. Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the area to be treated;

    11. Significant concurrent illness, such as diabetes, lupus, epilepsy or cardiac disorders, which might be aggravated as a result of treatment;

    12. Unable or unlikely to refrain from tanning, including the use of tanning booths, tanning spray or cream, during the course of the evaluation;

    13. Photosensitivity disorder that can be exacerbated by infrared light;

    14. Tattoos in the treatment areas;

    15. Dysplastic nevi in the treatment areas;

    16. Allergy or history of an allergy to the topical anesthetic used.

    17. Participation in a study of another device or drug within 3 months prior to study enrollment or during this study, and as per the Investigator's careful discretion, as long as not contradictory to any of the above criteria;

    18. Mentally incompetent, prisoner or evidence of active substance or alcohol abuse;

    19. Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Seaver Soon San Diego California United States

    Sponsors and Collaborators

    • Lumenis Ltd.

    Investigators

    • Principal Investigator: Seaver Soon, MD, Scripps Dermatology

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00657085
    Other Study ID Numbers:
    • LUM-ABU-HSET-0607-02
    First Posted:
    Apr 14, 2008
    Last Update Posted:
    Dec 12, 2008
    Last Verified:
    Dec 1, 2008
    Keywords provided by , ,

    Study Results

    No Results Posted as of Dec 12, 2008